Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure

Fundamental and Clinical Pharmacology

Volumn 20, Issue 5, 2006, Pages 503-505

  Morgan, Eric E ^a   Young, Martin E ^b   McElfresh, Tracy A ^a   Kung, Theodore A ^a   Hoit, Brian D ^c   Chandler, Margaret P ^a   Stanley, William C ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cardiac; Fatty acid oxidation; Metabolism; Mitochondria

Indexed keywords

ATRIAL NATRIURETIC FACTOR; MESSENGER RNA; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID OXIDATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; UPREGULATION;

ACYL-COA DEHYDROGENASE; ANIMALS; ATRIAL NATRIURETIC FACTOR; CARNITINE O-PALMITOYLTRANSFERASE; MALE; MYOCARDIAL INFARCTION; PALMITOYL-COA HYDROLASE; PROTEIN KINASES; RATS; RATS, WISTAR; RNA, MESSENGER; TRIMETAZIDINE; UP-REGULATION; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 33748678373     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2006.00424.x     Document Type: Article

References (9)

1. Belardinelli R., Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur. Heart J. (2001) 22 2164-2170.
2. Fragasso G., Piatti Md P.M., Monti L. et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. (2003) 146 E18.
3. Vitale C., Wajngaten M., Sposato B. et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur. Heart J. (2004) 25 1814-1821.
4. Tabbi-Anneni I., Helies-Toussaint C., Morin D., Bescond-Jacquet A., Lucien A., Grynberg A. Prevention of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover? J. Pharmacol. Exp. Ther. (2003) 304 1003-1009.
5. Stanley W.C., Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam. Clin. Pharmacol. (2003) 17 133-145.
6. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. (2005) 85 1093-1129.
7. D'Hahan N., Taouil K., Dassouli A., Morel J.E. Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6. Eur. J. Pharmacol. (1997) 328 163-174.
8. Morgan E.E., Faulx M.D., McElfresh T.A. et al. Validation of echocardiographic methods for assessing left ventricular dysfunction in rats with myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. (2004) 287 H2049-H2053.
9. Morgan E.E., Rennison J.H., Young M.E. et al. Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am. J. Physiol. Heart Circ. Physiol. (2006) 290 H1899-H1904.